Elitek
(Rasburicase)ApprovedProtein / enzyme
Rasburicase is used to treat high uric acid levels in the blood that can occur in cancer patients, especially those with blood cancers being treated with chemotherapy. It helps prevent kidney damage and other complications from uric acid buildup.[2] Elitek is currently approved and in use across 5 indications[4].[1]
Elitek is one of 129 small molecule programs targeting Lymphoma. It is currently in Approved.
5
Indications
21
Total Trials
1
Active Trials
128
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tumor Lysis Syndrome6 trials
Hyperuricemia4 trials
Leukemia2 trials
Graft Versus Host Disease1 trial
7 more indications
Hematologic Malignancies1 trial
Acute Lymphoblastic Leukemia1 trial
Arthritis1 trial
Rasburicase Treatment in Chronic Gouty Arthritis
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT05312268·60 enrolled
Acute Leukemia1 trial
Regulatory
FDA Approval Timeline[5]
Jul 12, 2002
ELITEK
BLA BLA103946
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Elitek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rasburicase. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details